Product Description
Mechanisms of Action: MAO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Brazil | Chile | China | Colombia | Dominican Republic | Ecuador | India | Indonesia | Ireland | Italy | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Taiwan | Turkey | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Helicobacter Infections|Communicable Diseases|Gastrointestinal Cancer
Phase 2: Helicobacter Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2400087082 | N/A |
Not yet recruiting |
Helicobacter Infections |
2026-06-30 |
2024-07-19 |
Treatments |
|
| ChiCTR2500096313 | N/A |
Not yet recruiting |
Helicobacter Infections |
2026-06-30 |
|||
| ChiCTR2500103842 | N/A |
Not yet recruiting |
Helicobacter Infections |
2026-04-30 |
|||
| ChiCTR2500096016 | N/A |
Not yet recruiting |
Helicobacter Infections |
2026-01-01 |
|||
| ChiCTR2400093569 | N/A |
Not yet recruiting |
Helicobacter Infections |
2025-07-31 |
|||
| KY20240123-05 | N/A |
Not yet recruiting |
Helicobacter Infections |
2024-12-31 |
2024-04-02 |
Primary Endpoints|Treatments |
|
| ChiCTR2300073347 | N/A |
Not yet recruiting |
Helicobacter Infections |
2024-12-31 |
2023-09-03 |
Treatments |
|
| ChiCTR2300073141 | N/A |
Recruiting |
Helicobacter Infections |
2024-03-01 |
2023-07-04 |
Treatments |
|
| CS-HP001 | N/A |
Unknown status |
Helicobacter Infections|Communicable Diseases |
2024-02-01 |
2024-12-03 |
||
| ChiCTR2200064872 | N/A |
Not yet recruiting |
Helicobacter Infections |
2023-10-31 |
|||
| 2021-SDU-QILU-G101 | N/A |
Completed |
Helicobacter Infections |
2023-02-10 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| JW-Hp2021 | N/A |
Unknown status |
Communicable Diseases |
2022-12-31 |
2024-08-02 |
Primary Endpoints|Treatments|Trial Status |
|
| ChiCTR2100052604 | N/A |
Not yet recruiting |
Helicobacter Infections |
2022-12-31 |
|||
| xucanxia2020 | N/A |
Unknown status |
Helicobacter Infections|Communicable Diseases |
2022-12-01 |
2024-06-04 |
Primary Endpoints|Treatments|Trial Status |
|
| ChiCTR1900023366 | N/A |
Not yet recruiting |
Gastrointestinal Cancer |
2022-09-30 |
|||
| 2021-SDU-QILU-G010 | N/A |
Unknown status |
Helicobacter Infections |
2022-06-30 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| 2021-SDU-QILU-G003 | N/A |
Unknown status |
Helicobacter Infections |
2022-06-30 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| ChiCTR1900024682 | N/A |
Recruiting |
Helicobacter Infections |
2022-06-30 |
|||
| 2020-SDU-QILU-G101 | N/A |
Completed |
Helicobacter Infections |
2022-06-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| ChiCTR2000030775 | N/A |
Not yet recruiting |
Helicobacter Infections |
2021-12-31 |
|||
| ChiCTR2000040051 | N/A |
Recruiting |
Helicobacter Infections |
2021-06-08 |
|||
| NCT06823791 | P2 |
Completed |
Helicobacter Infections |
2024-07-30 |
2025-02-13 |
Primary Endpoints|Treatments |
|
| NCT05718609 | P4 |
Unknown status |
Helicobacter Infections|Communicable Diseases |
2024-03-01 |
2025-01-03 |
||
| 2019-SDU-QILU-G226 | P4 |
Unknown status |
Helicobacter Infections |
2022-10-30 |
2023-11-03 |
Primary Endpoints|Treatments|Trial Status |
|
| 2021-SDU-QILU-G226 | P4 |
Unknown status |
Helicobacter Infections |
2022-10-01 |
2023-11-03 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|